Brightmind.AI is developing therapeutic TMS (transcranial magnetic stimulation) devices for home use, with a first indication of migraine.
The standard approach to treating neurological and neuropsychiatric disorders is administration of pharmaceutical drugs. However, many patients do not find adequate relief with existing treatments, and side effects can be severe, leading to reduced quality of life and poor patient compliance. Non-invasive brain stimulation technologies have emerged as promising solutions. rTMS (repetitive transcranial magnetic stimulation), in particular, has been shown to be highly effective in treating brain disorders.
The founders of Brightmind.AI realized that most patients who could medically benefit from rTMS therapy cannot access it due to the high cost and the need to travel to a clinic for administration. Brightmind.AI’s ambition is to miniaturize rTMS to the extent that it becomes both portable and affordable. For a first indication of migraine, clinically proven stimulation protocols will be coupled with an EEG-based feedback system to ensure optimal outcomes through regular use of the device by patients in their own homes. We are convinced that neuromodulation technologies can address many unmet needs in the neuropsychiatric and mental health space. Brightmind.AI, with its young and dynamic co-founders Florian Lerchbammer-Kreith and Tamara Gerbert, is poised to lead a transformation of the industry.